CD36 promotes the epithelial-mesenchymal transition and metastasis in cervical cancer by interacting with TGF-β

• Published in: Journal of translational medicine 2019-10, Vol.17 (1), p.352-352, Article 352
• Main Authors: Deng, Min, Cai, Xiaodong, Long, Ling, Xie, Linying, Ma, Hongmei, Zhou, Youjian, Liu, Shuguang, Zeng, Chao
• Format: Article
• Language: English
• Subjects: CD36; Cervical cancer; EMT; Metastasis; TGF-β
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-019-2098-6

Accumulating evidence indicates that CD36 initiates metastasis and correlates with an unfavorable prognosis in cancers. However, there are few reports regarding the roles of CD36 in initiation and metastasis of cervical cancer. Using immunohistochemistry, we analyzed 133 cervical cancer samples for CD36 protein expression levels, and then investigated the correlation between changes in its expression and clinicopathologic parameters. The effect of CD36 expression on the epithelial-mesenchymal transition (EMT) in cervical cancer cells was evaluated by Western immunoblotting analysis. In vitro invasion and in vivo metastasis assays were also used to evaluate the role of CD36 in cervical cancer metastasis. In the present study, we confirmed that CD36 was highly expressed in cervical cancer samples relative to normal cervical tissues. Moreover, overexpression of CD36 promoted invasiveness and metastasis of cervical cancer cells in vitro and in vivo, while CD36 knockdown suppressed proliferation, migration, and invasiveness. We demonstrated that TGF-β treatment attenuated E-cadherin expression and enhanced the expression levels of CD36, vimentin, slug, snail, and twist in si-SiHa, si-HeLa, and C33a-CD36 cells, suggesting that TGF-β synergized with CD36 on EMT via active CD36 expression. We also observed that the expression levels of TGF-β in si-SiHa cells and si-HeLa cells were down-regulated, whereas the expression levels of TGF-β were up-regulated in C33a-CD36 cells. These results imply that CD36 and TGF-β interact with each other to promote the EMT in cervical cancer. Our findings suggest that CD36 is likely to be an effective target for guiding individualized clinical therapy of cervical cancer.